Chronic Myeloid Leukemia (CML)

Oncology·MeSH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Prevalence

12.0 / 100K

Incidence

1.9 / 100K/yr

7 drugs in development·3 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
asciminib	Novartis AG (NVS)

Phase 2(3)

Drug	Company
abl001/asciminib	Novartis AG (NVS)
Asciminib	Novartis AG (NVS)
tern-701	Terns Pharmaceuticals, Inc. (TERN)

Preclinical(1)

Drug	Company
BCR-ABL TKI	Theseus Pharmaceuticals, Inc. (THRX)

Phase 4(2)

Drug	Company
bosutinib	Novartis AG (NVS)
imatinib	Novartis AG (NVS)

BioSniper tracks 7 drugs in development for Chronic Myeloid Leukemia (CML) across 3 companies.

There are 2 clinical trials targeting Chronic Myeloid Leukemia (CML) tracked by BioSniper.

The estimated prevalence of Chronic Myeloid Leukemia (CML) is approximately 12.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.